Next Article in Journal
COVID-19 Vaccine Acceptability and Its Determinants in Mozambique: An Online Survey
Next Article in Special Issue
Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination
Previous Article in Journal
COVID-19 Associated Rhino-Orbital Mucormycosis Complicated by Gangrenous and Bone Necrosis—A Case Report from Honduras
Previous Article in Special Issue
Acceptance of COVID-19 Vaccination in Cancer Patients in Hong Kong: Approaches to Improve the Vaccination Rate
Article

A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2

1
Shenzhen Geno-Immune Medical Institute, Shenzhen 518000, China
2
School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China
3
Wellness Medical Center, Rochelle Park, NJ 07662, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Ralph A. Tripp, Steven B. Bradfute and Scott Anthony
Vaccines 2021, 9(8), 827; https://doi.org/10.3390/vaccines9080827
Received: 2 July 2021 / Revised: 23 July 2021 / Accepted: 24 July 2021 / Published: 27 July 2021
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific cellular immune response has been shown to play a critical role in preventing severe illness or death in patients infected with SARS-CoV-2 or its variants. Given the multiple T-cell epitopes shared by wild-type virus and its variants, we hypothesized that vaccines that target multiple T-cell epitopes of SARS-CoV-2 may provide a “universal protection” against the wild-type virus as well as its variants, even the heavily mutated ones. To test this, we assessed SARS-CoV-2-specific T-cell precursors in healthy individuals using overlapping peptide pools of SARS-CoV-2 structural and functional proteins, including spike (S), membrane (M), envelope (E), nucleocapsid (N), and protease (P) proteins as target antigens. Diverse T-cell precursor frequencies specific to these viral antigens were detected in healthy individuals, including high, medium, low, and no responders. This was further confirmed by efficient induction of anti-SARS-CoV-2 T-cell immune responses using ex vivo dendritic cell (DC)/T cell coculture. The results demonstrated T-cell responses consistent with the precursor frequencies of each of the individuals tested. Importantly, the combination of all five viral peptide pools induced the strongest cellular immune response, and further, after a DC-peptides re-stimulation, even the no responders developed an increased anti-viral T-cell response. These analyses recapitulate the presence of a broad anti-SARS-CoV-2 cellular immunity even in an immune naïve population, which could be enhanced by antigen presenting cells presenting the overlapping antigenic peptides. Given the critical role of cellular immunity in COVID-19 protection, these results have important implications for vaccine design and immunotherapy in fighting SARS-CoV-2 and its variants. View Full-Text
Keywords: COVID-19; SARS-CoV-2; cellular immunity; vaccine COVID-19; SARS-CoV-2; cellular immunity; vaccine
Show Figures

Graphical abstract

MDPI and ACS Style

Chang, C.-W.; Liu, Y.; Jiao, C.; Liu, H.; Gong, J.; Chen, X.; Chang, L.-J. A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2. Vaccines 2021, 9, 827. https://doi.org/10.3390/vaccines9080827

AMA Style

Chang C-W, Liu Y, Jiao C, Liu H, Gong J, Chen X, Chang L-J. A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2. Vaccines. 2021; 9(8):827. https://doi.org/10.3390/vaccines9080827

Chicago/Turabian Style

Chang, Cheng-Wei, Yuchen Liu, Cheng Jiao, Hongwei Liu, Jie Gong, Xiaochuan Chen, and Lung-Ji Chang. 2021. "A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2" Vaccines 9, no. 8: 827. https://doi.org/10.3390/vaccines9080827

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop